\u003cp\u003eKidney disease and cancer are frequent comorbidities that require specialized knowledge and expertise from both the nephrologist and the oncologist. Written by three pioneers in this growing subspecialty, \u003ci\u003eOnco-Nephrology\u003c/i\u003e provides \u003cb\u003eauthoritative, definitive coverage of the mechanism and management of these two life-threatening diseases\u003c/b\u003e. This unique, single-volume resource covers current protocols and recommends management therapies to arrest kidney failure and allow oncologic treatments to continue and succeed\u003ci\u003e.\u003c/p\u003e\u003c/i\u003e\u003cul\u003e\u003cli\u003eAddresses \u003cb\u003eacute and chronic kidney diseases that develop from a variety of cancers\u003c/b\u003e. This includes direct kidney injury from the malignancy, paraneoplastic effects of the cancer, and various cancer agents used to treat the malignancy.\u003c/li\u003e\u003cli\u003eDiscusses \u003cb\u003ekey issues regarding kidney disease in patients with cancer\u003c/b\u003e, including conventional chemotherapeutic regimens and new novel therapies (targeted agents and immunotherapies) or the malignancies themselves that may promote kidney injury; patients with chronic kidney disease who acquire cancer unrelated to renal failure; and kidney transplantation, which has been shown to carry an increased risk of cancer.\u003c/li\u003e\u003cli\u003eContains \u003cb\u003ededicated chapters for each class of the conventional chemotherapeutic agents\u003c/b\u003e, targeted cancer agents, and cancer immunotherapies including the basic science, pathogenic mechanisms of injury, clinical manifestations, and treatment.\u003c/li\u003e\u003cli\u003eIncludes \u003cb\u003especial chapters\u003c/b\u003e devoted to the individual classes of chemotherapies that relate to kidney disease for quick reference. Discusses \u003cb\u003eincreasingly complex problems\u003c/b\u003e due to more numerous and specialized anti-cancer drugs, as well as increased survival rates for both cancer and renal failure requiring long-term patient care.\u003c/li\u003e\u003cli\u003eCovers \u003cb\u003eanti-VEGF (antivascular endothelial growth factor) agents and cancer immunotherapies\u003c/b\u003e â treatments that are being recognized for adverse kidney effects.\u003c/li\u003e\u003cli\u003eUtilizes a clear, logical format \u003cb\u003ebased on the ASN Core Curriculum for Onco-Nephrology\u003c/b\u003e, making this reference an excellent tool for board review, as well as a practical resource in daily practice.\u003c/li\u003e\u003cli\u003e\u003cb\u003eEnhanced\u003c/b\u003e \u003cb\u003eeBook version included with purchase. \u003c/b\u003eYour enhanced eBook allows you to access all of the text, figures, and references from the book on a variety of devices.\u003c/li\u003e\u003c/ul\u003e
nl
en